Bristol Myers Squibb Reports Positive Phase 3 Data for Alzheimer's Psychosis Treatment KarXT

Bristol Myers Squibb (BMY) has announced positive results from two Phase 3 clinical trials evaluating its drug candidate, KarXT (xanomeline and trospium chloride). The data indicates that the treatment significantly improved scores related to hallucinations and delusions in patients suffering from Alzheimer's disease psychosis. The studies also demonstrated that the asset was well tolerated by participants. This development marks a significant milestone for BMY as it seeks to address an unmet medical need in the neuropsychiatry space, potentially providing a new therapeutic option for managing psychotic symptoms associated with dementia.

2 articles from 1 source · updated

Coverage